The Patent Finder

Lumos Pharma, Inc.

12 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 28, 2027
    The maintenance fee for Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes (US 9,090,643) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Compactable Oral Formulations of Ibutamoren (US 11,969,416) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,442,706Methods for treating sarcopenia with a growth hormone secretagogue
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,090,643Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,732,035Salts and prodrugs of 1-methyl-D-tryptophan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,207,990Salts and prodrugs of 1-methyl-D-tryptophan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,763,919Detecting and treating growth hormone deficiency
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,105,352Detecting and treating growth hormone deficiency
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,898,472Detecting and treating growth hormone deficiency
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,234,969Detecting and treating growth hormone deficiency
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,485,705Salts and prodrugs of 1-methyl-d-tryptophan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,539,293Detecting and Treating Growth Hormone Deficiency
In force
 · Low confidence
In forceLow confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 7 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited